Philip Beer

• Following the separate roundtable discussions, this session is dedicated to the roundtable leaders to share insights, outcomes, and further questions raised on each table

• This will be a panel format, taking audience questions to close off the day

• See how Step Pharma is leveraging data-driven discovery of replication stress as a predictive biomarker, linking novel agents with ATR and WEE1 synergy

• Sharing preclinical insights while outlining the translational challenges of moving from complex preclinical signatures to clinical assays

• Balancing biomarker complexity with clinical feasibility to inform future DDR combination strategies